man
transmiss
studi
two
type
transmiss
presum
viral
hepat
defin
first
infecti
hepat
ih
type
rel
short
incub
period
day
usual
day
may
transmit
either
fecalor
parenter
rout
numer
common
sourc
epidem
attribut
contamin
food
watjer
milk
describ
secondari
infect
among
close
contact
common
household
particularli
larg
institut
mental
retard
children
ih
may
becom
establish
endem
problem
second
type
serum
hepat
sh
type
b
long
highli
variabl
incub
period
day
year
ago
sh
thought
transmiss
parenter
inocul
recent
transmiss
studi
epidemiolog
observ
howev
provid
good
evid
infect
agent
may
also
acquir
oral
rout
like
ih
may
becom
endem
institut
set
krugman
et
al
review
deal
discoveri
character
immunolog
etiolog
signific
australia
antigen
new
antigen
specif
appear
serum
patient
serum
hepat
carri
characterist
lipoprotein
particl
addit
origin
name
given
relationship
viral
hepat
becam
known
antigen
also
given
follow
design
au
sh
antigen
aush
antigen
hepat
antigen
hepatitisassoci
antigen
haa
time
clear
evid
term
refer
singl
entiti
sera
person
receiv
multipl
transfus
prove
valu
detect
serum
isoantigen
use
approach
ouchterloni
techniqu
twodimension
doubl
immunodiffus
allison
blumberg
blumberg
et
al
abl
defin
new
lipoprotein
polymorph
ag
system
detail
origin
later
immunodiffus
method
discuss
section
v
c
continu
search
blumberg
cowork
identifi
new
precipit
antigen
help
serum
two
multipl
transfus
hemophiliac
blumberg
blurnberg
et
al
sera
contain
antibodi
react
serum
australian
aborigin
give
singl
line
precipit
precipit
compon
design
australia
antigen
appear
repres
singl
antigen
determin
clearli
distinct
previoudi
tlcscribcd
human
seruin
isoantigen
considcrctl
first
w
anoth
cxampl
serum
protein
polyniorphisin
possess
australia
antigen
held
distinguish
phcnotypc
au
j
reflect
genotyp
aulaul
allel
postul
autosom
recess
thu
individu
lack
australia
antigen
phenotyp
au
would
bc
either
homozyg
auau
heterozyg
auau
domin
au
allel
act
prevent
synthesi
detect
antigen
blumberg
et
al
hypothesi
simpl
genet
determin
australia
antigen
later
modifi
discoveri
peculiar
associ
leukemia
syndrom
hepat
n
meantirnc
howev
led
notabl
seri
studi
blurnberg
associ
blumberg
et
al
blumberg
et
al
look
thc
antigen
variou
popul
cliff
erent
part
world
earli
serum
survey
soon
reveal
uneven
distribut
australia
au
antigen
differ
human
popul
data
shown
tabl
taken
blumberg
et
al
possess
express
antigen
rel
common
among
peopl
southeastern
asia
pacif
island
well
australian
aborigin
contrast
frequenc
gener
unit
state
popul
low
variat
differ
popul
appear
first
sight
provid
possibl
support
hypothesi
genet
control
synthesi
au
macromolecul
studi
famili
made
test
suggest
antigen
might
specifi
autosom
recess
gene
data
obtain
suffici
provid
firm
support
thesi
although
rule
two
later
piec
evid
combin
make
earli
simpler
genet
interpret
less
convinc
began
appar
environment
factor
significantli
affect
detect
au
antigen
serum
observ
princ
soon
gener
confirm
durat
antigen
serum
usual
transient
day
sever
week
occasion
persist
indefinit
gile
et
al
zuckerman
taylor
simpl
presenc
absenc
gene
product
inadequ
explain
find
recent
howev
hypothesi
modifi
state
persist
presenc
australia
antigen
serum
ie
au
phenotyp
reflect
peculiar
individu
suscept
develop
chronic
infect
varieti
agent
includ
serum
hepat
specif
associ
au
antigen
wide
infra
tendenc
toward
develop
chronic
carrier
state
affect
least
one
autosom
recess
gene
still
design
blumberg
data
support
expand
hypothesi
deriv
studi
island
popul
cebu
philippin
bougainvil
new
guinea
hygien
sanitari
condit
warrant
assumpt
variou
oral
transmit
infect
includ
form
viral
hepat
krugman
et
al
would
endem
popul
would
ampl
opportun
exposur
individu
time
infecti
agent
result
far
appear
disprov
hypothesi
mani
data
presum
hepatitissatur
popul
demand
analysi
novel
provoc
hypothesi
accept
near
establish
n
studi
variou
group
within
unit
state
blumberg
colleagu
observ
earli
au
antigen
unusu
frequent
individu
certain
form
leukemia
associ
later
found
true
also
patient
syndrom
lepromat
leprosi
hepat
blumberg
et
al
b
worker
note
among
children
syndrom
institut
show
markedli
higher
frequenc
au
antigen
serum
remain
home
vs
sutnick
et
al
extend
observ
investig
note
staff
mental
hospit
institut
likewis
includ
auposit
gener
popul
becam
appar
environment
condit
institut
import
factor
determin
frequenc
possess
au
antigen
suggest
relationship
acquir
factor
transmit
infecti
agent
strengthen
find
strikingli
high
proport
antigen
possessor
among
patient
diseas
deprcssion
disturb
immunc
function
niight
expect
eg
leukemia
lepromat
leprosi
recent
exampl
tendenc
nurs
personnel
well
patient
acquir
au
antigen
seen
experi
chronic
renal
hemodialysi
unit
london
et
al
turner
white
first
indic
unusu
high
preval
au
antigen
serum
hepat
patient
publish
blumberg
et
al
soon
afterward
princ
okochi
murakami
demonstr
appear
au
sh
antigen
serum
individu
usual
week
experiment
inocul
blood
transfus
case
antigen
persist
one
sever
week
disappear
case
respect
still
present
latest
serum
test
month
inocul
other
confirm
amplifi
find
eg
hirschman
et
al
whose
auposit
au
case
sh
retain
antigen
month
onset
gile
et
al
report
persist
au
least
year
person
receiv
strain
sh
agent
n
patient
serum
glutam
oxaloacet
glutam
pyruv
transaminas
rose
abnorm
high
level
usual
day
initi
appear
au
thereaft
correl
elev
enzym
level
serum
antigen
vari
wide
n
case
overt
diseas
symptom
began
day
au
antigen
first
becam
detect
find
indic
special
tempor
relationship
au
antigen
sh
form
viral
hepat
contrast
unchang
presenc
absenc
leukemia
syndrom
lepromat
leprosi
associ
au
antigen
viral
hepat
confirm
mani
laboratori
princip
point
disagr
question
whether
implic
form
viral
hepat
specif
limit
longincub
sh
form
suffic
say
studi
involv
welldocu
experiment
produc
infect
antigen
regularli
found
almost
case
sh
detect
shortincub
diseas
ih
type
princ
gile
et
al
furthermor
studi
sever
commonsourc
outbreak
ih
type
hepat
au
antigen
demonstr
patient
concern
mosley
et
al
noteworthi
none
group
volunt
experiment
infect
mouth
akiba
strain
h
neef
stoke
develop
detect
antigen
one
individu
alreadi
possess
au
antigen
serum
inocul
continu
throughout
cours
experiment
infect
howev
possibl
result
infect
ihtyp
agent
case
declin
concentr
alreadi
circul
au
antigen
fourth
eighth
week
inocul
remain
seen
whether
coincident
fluctuat
causal
relat
experiment
introduc
agent
eg
result
interfer
au
antigen
synthesi
cellular
level
due
block
effect
circul
inhibitor
crossreact
antibodi
initi
experi
test
second
possibl
far
yield
neg
result
thu
au
antigen
consist
found
case
longincub
viral
hepat
signific
report
presenc
sporad
case
design
h
still
determin
london
et
al
note
au
rare
detect
acut
phase
sera
obtain
children
hepat
find
support
subsequ
studi
report
among
form
acut
chronic
liver
diseas
includ
drug
hepat
biliari
cirrhosi
alcohol
cirrhosi
postnecrot
cirrhosi
infcctiou
inononuclcosih
au
nitigen
remark
absent
gock
kavci
except
chronic
activ
hepat
au
mtigen
bccii
found
unit
state
wright
et
al
gitnick
et
al
australia
mathew
mackay
howev
far
found
case
england
fox
et
al
denmark
reinick
nordenfelt
chile
velasco
katz
serolog
reaction
australia
au
antigen
antibodi
dealt
separ
follow
section
p
section
consid
properti
antigen
particl
carri
au
specif
carli
studicn
alter
blurnberg
investig
stain
properti
au
antigenantibodi
precipit
agar
gel
strong
reaction
obtain
protein
stain
azocarmin
also
weak
variabl
affin
lipid
stain
sudan
black
intens
reaction
less
given
serum
lipoprotein
particip
protein
reactiv
au
antigen
also
shown
sensit
trypsin
c
hour
treatment
sodiuni
dodecyl
sulfat
c
hour
le
treatment
diethyl
ether
fluorocarbon
eff
cct
morpholog
auantigen
particl
discuss
antigen
specif
alter
level
activ
remain
unchang
may
even
increas
appear
report
presenc
carbohydr
nucleic
acid
associ
australia
particl
antigen
specif
inde
bc
nuclcic
acid
evid
present
concentr
compar
ribonucl
acid
full
dantigen
poliovirion
immunodiffus
band
full
empti
c
poliovirion
au
antigen
stain
acridin
orang
cf
cowan
grave
polioviru
band
stain
fluoresc
brightli
wherea
c
au
band
remain
complet
unstain
le
bouvier
long
particul
natur
known
au
antigen
suspect
high
molecular
weight
alter
sinc
exclud
gel
sephadex
moreov
charact
precipit
band
agar
indic
antigen
particl
macromolecul
distinctli
larger
presum
igg
antibodi
molecul
react
recent
immunodiffus
studi
given
figur
xg
n
equival
posit
au
antigenantibodi
precipit
ie
fraction
distanc
antigen
antibodi
cup
precipit
form
reactant
meet
optim
proport
react
antibodi
known
igg
class
diffus
coeffici
antibodi
taken
x
lo
cf
van
regenmortel
earli
studi
adsorpt
chromatographi
deaecellulos
au
antigen
elut
phosphat
ph
igg
togeth
slightli
ahead
plipoprotein
iga
igm
albumin
alter
subject
immunoelectrophoresi
au
antigen
somewhat
resembl
mobil
nlglobulin
alter
buoyant
densiti
antigenbear
particl
intermedi
serum
lipoprotein
protein
first
studi
done
flotat
kbr
antigen
activ
associ
fraction
densiti
gmml
alter
blumberg
n
recent
studi
gener
agreement
intermedi
densiti
discrep
precis
figur
maxima
gerin
e
al
le
bouvier
hierholz
millman
et
al
gmml
barker
e
al
sucros
gerin
et
al
le
bouvier
hierholz
potassium
tartrat
gerin
e
al
treatment
ether
fluorocarbon
sodium
deoxychol
densiti
increas
eg
gerin
e
al
sucros
le
bouvier
hierholz
one
studi
gerin
et
al
freez
thaw
treatment
tween
au
antigen
fraction
twice
band
cscl
separ
rate
sediment
sucros
caus
fall
buoyant
densiti
cscl
also
result
emerg
signific
amount
au
materi
densiti
gmml
yet
known
repres
densiti
would
compat
nucleoprotein
sediment
coeffici
auantigen
particl
report
one
studi
adenoassoci
viru
aavl
use
marker
gerin
et
al
determin
made
sucros
w
rpm
hour
use
test
materi
au
antigen
purifi
two
sequenti
equilibrium
centrifug
cscl
densiti
gradient
ident
sediment
coeffici
found
princ
n
anoth
studi
done
similar
condit
use
serum
materi
test
le
bouvier
valu
au
antigen
activ
found
intermedi
igm
empti
polioviru
capsid
reason
appar
discrep
still
discov
materi
examin
consist
preselect
segment
popul
auantigen
particl
eg
peak
fraction
cscl
isopycn
centrifug
valu
obtain
buoyant
densiti
sediment
coeffici
may
fall
within
quit
narrow
rang
test
materi
untreat
unheat
serum
valu
show
greater
spread
sometim
one
peak
suggest
consider
particl
heterogen
fig
clear
degre
aggreg
auantigen
particl
affect
determin
size
sediment
diffus
characterist
likewis
capac
react
serolog
test
vide
infra
p
purcel
et
al
report
decreas
au
antigen
titer
detect
immunodiffus
heat
minut
could
caus
aggreg
without
degrad
sinc
complementfix
antigen
destroy
overnight
incub
temperatur
gerin
et
al
result
indic
appreci
loss
antigen
activ
test
immunodiffus
heat
hour
millman
et
al
minut
c
year
room
temperatur
hierholz
et
al
gerin
et
al
report
mark
drop
au
antigen
titer
experi
au
antigen
fraction
densiti
cscl
subject
veloc
sediment
sucros
point
particl
aggreg
probabl
reason
loss
complementfix
activ
au
antigen
affect
howev
incub
ph
hour
room
temperatur
exposur
ether
vv
either
overnight
c
hour
room
temperatur
peculiar
geograph
distribut
diseas
associ
au
antigen
began
appreci
question
aros
whether
antigen
might
relat
might
transmiss
agent
particular
viru
bayer
et
al
therefor
examin
electron
microscop
techniqu
neg
stain
sodium
silicotungst
auf
fraction
deriv
sampl
serum
separ
sucros
densiti
gradient
electrophoresc
cellulos
acet
made
astonish
di
isopycn
centrifug
cesium
chlorid
au
antigen
differ
sera
serum
ml
mix
ml
ww
cscl
p
n
spun
rpm
hour
spinco
sw
rotor
fraction
ml
collect
buoyant
densiti
determin
weigh
aliquot
coveri
round
ovoid
particl
nm
diamet
possess
suggest
knoblik
surfac
project
nm
diamet
particl
seem
central
diamet
core
appear
empti
shell
fill
stain
particl
seen
heavier
fraction
lack
au
antigen
fraction
correspond
densiti
deriv
auneg
sera
furthermor
aggreg
particl
could
seen
electron
microscop
mixtur
au
fraction
rabbit
antisera
contain
antiau
precipitin
concentr
polioviru
antigen
igm
measur
unit
milligram
hut
arp
girrn
ns
n
function
zy
fraction
distanc
antigen
antihodi
cup
precipit
take
place
cf
p
anoth
alnicida
waterson
form
appear
regular
transvers
striatioii
ofteii
inad
eriod
iini
waterson
tubul
may
attain
length
nm
often
variabl
widcr
round
swclling
hul
bou
forniwt
oric
end
may
exhibit
sharpli
angl
even
rightangl
bend
well
lesscr
degre
smoother
curvatur
bayer
et
al
alnieida
et
nl
zuckerman
barker
et
al
studi
sizc
distribut
particl
present
au
fraction
cscl
densiti
gradient
treatment
ether
fluorocarbon
genetron
figur
paper
modif
form
basi
fig
show
larger
modal
particl
diamet
nm
broader
spread
particl
size
untreat
prepar
treatincnt
particl
appear
smaller
modal
diamet
nm
sharpli
outlin
evenli
dispers
moder
increas
buoyant
densiti
vide
supra
virtual
tubular
form
disappear
au
antigen
titer
measur
complement
fixat
anyth
somewhat
higher
extract
barker
et
al
interpret
find
mean
outer
lipid
coat
nm
thick
case
probabl
also
attach
antiau
antibodi
remov
extract
sinc
treatment
lipid
solvent
appear
modifi
antigen
specif
would
seem
put
lipid
coat
complet
cover
particl
surfac
possibl
might
bulk
lipid
present
interparticul
cement
larger
round
ovoid
particl
fact
made
two
unit
particl
monad
least
elong
form
neg
stain
potassium
phosphotungst
ph
serum
centrifug
rpm
hour
spinco
sw
rotor
pellet
resuspend
loox
concentr
tri
ph
note
spheric
ovoid
particl
diamet
nm
short
tubular
form
length
bar
equival
nm
b
au
particl
agglutin
antiau
antibodi
suspens
seen
fig
mix
antibodycontain
serum
b
multitransfus
patient
held
overnight
examin
neg
stain
describ
note
aggreg
particl
also
includ
occasion
tubul
c
au
particl
concentr
partial
purifi
sernm
fraction
two
sequenti
equilibrium
centrifug
cscl
densiti
gradient
cf
gerin
et
al
final
au
antigencontain
fraction
dilut
volum
buffer
particl
sediment
rpm
hour
spinco
sw
rotor
pellet
resuspend
buffer
give
concentr
respect
origin
volum
serum
droplet
particl
suspens
examin
neg
stain
n
addit
characterist
round
particl
occasion
short
tubul
seen
well
empti
particl
stain
penetr
indebt
dr
walter
hierholz
prepar
might
consist
string
monad
other
would
rel
empti
lipoprotein
sac
possibl
contain
termin
occasion
intercalari
monad
base
hypot
hesi
lipid
would
dissolv
upon
exposur
ether
fluorocarbon
larger
structuresdyad
triad
etc
well
tubular
pleiadswould
dismemb
compon
monad
second
class
particl
observ
serum
au
hepat
patient
dane
et
al
patient
whose
serum
contain
particl
also
show
lesser
number
complex
viruslik
particl
nm
diamet
consist
inner
bodi
diamet
shell
outer
coat
nm
thick
larg
small
particl
form
mix
aggreg
treat
antiau
sera
suggest
share
surfac
antigen
possibl
larger
form
may
sh
viru
smaller
particl
tubul
may
repres
surplu
viruscoat
materi
find
larger
particl
certain
au
sera
confirm
cossart
field
gust
et
al
natur
signific
australia
particl
pose
biggest
singl
question
present
microbiolog
hepat
surprisingli
viruslik
appear
frequent
led
tacit
assumpt
inde
virion
respons
infect
extrem
opposit
view
suggest
sole
repres
specif
modifi
neoantigen
cell
fragment
produc
respons
infect
yet
undiscern
viru
consid
later
p
also
consid
view
particl
relat
causal
viru
part
whole
virion
analog
rather
envelop
myxovirus
compos
unalt
hostcel
materi
well
virusspecifi
virusmodifi
molecul
great
major
envelop
fiq
electron
micrograph
au
particl
serum
patient
chronic
anictcr
hepat
magnif
x
courtesi
dr
virginia
killbi
b
au
particl
fraction
rate
zonal
sediment
experi
illustr
fig
part
cxamin
neg
stain
indic
fig
note
round
particlc
nm
diamet
tubul
nunier
longer
tliun
seen
fig
sonic
show
shnrp
angul
note
also
tlir
appear
lcore
c
soni
spheric
particl
core
bulb
h
elong
form
occasion
tubul
show
illdefin
appar
regular
trnnsvers
striation
length
bar
fig
equival
mi
c
e
samc
fraction
inixcd
serum
contain
antiau
antibodi
note
aggreg
made
round
tubular
au
particl
tubul
fig
show
crossstriat
incomplet
empti
diff
erent
structur
though
presum
markedli
size
infect
particl
cf
mccollutn
barker
et
al
particl
auposit
serum
pass
celit
filter
fraction
centrifug
cscl
gradient
au
fraction
examin
electron
microscop
neg
stain
phosphotungst
acid
exposur
ether
equal
part
hour
volum
calcul
spheric
particl
given
diamet
basi
close
untreat
au
particl
diamet
nm
volum
rang
nm
ie
time
volum
nmdiamet
monad
particl
figur
modifi
barker
et
al
auantigen
particl
must
evid
attain
impress
concentr
serum
detect
readili
whether
particl
electron
microscopi
antigen
reactant
immunodiffus
comparison
correspond
concentr
requir
polioviru
one
may
calcul
individu
sera
must
often
contain
particlesor
pgper
inillilitcr
serum
thcre
appear
publish
report
yet
partick
count
one
serum
examin
found
particlesrnl
melnick
tubular
form
offer
addit
ground
regard
auantigen
particl
conceiv
relat
sort
micromyxoviru
proport
form
appear
vari
consider
one
individu
anoth
likewis
within
given
individu
differ
time
put
forward
suggest
tubul
repres
matur
form
infect
agent
elabor
particularli
patient
chronic
hepat
asymptomat
persist
carrier
spheric
ovoid
small
pleomorph
particl
would
repres
less
well
organ
form
agent
question
signific
differ
structur
differ
type
patient
taken
p
infect
particl
concentr
per
se
test
directli
human
subject
previous
identifi
icterogen
sera
found
contain
au
antigen
inocul
variou
primat
attempt
produc
detect
infect
wide
varieti
cell
organ
cultur
current
undertaken
variou
laboratori
find
yet
publish
au
antigen
morpholog
characterist
particl
found
occasion
individu
sever
primat
speci
includ
chimpanze
orangutan
gibbon
hirschman
et
al
serial
serum
specimen
obtain
earlier
transmiss
attempt
chimpanze
inocul
materi
known
contain
au
antigen
test
immunodiffus
evid
circul
au
detect
mccollum
au
antigen
report
liver
cell
patient
hepat
mean
immunofluoresc
test
fluoresceinlabel
igg
fraction
antiau
rabbit
antiserum
millman
et
al
liver
biopsi
patient
examin
form
viral
hepat
includ
one
chronic
anicter
au
antigen
serum
control
without
liver
diseas
except
one
hepatoma
biopsi
tissu
minc
cultur
medium
drop
result
cell
suspens
spread
slide
airdri
fix
aceton
discret
fluoresc
granul
seen
within
nuclei
per
nucleu
almost
everi
cell
biopsi
hepat
patient
absent
control
specif
reaction
shown
block
test
unconjug
antiau
antiserum
subsequ
addit
label
antibodi
produc
fluoresc
see
also
section
v
f
tissu
examin
includ
sternal
bone
marrow
au
syndrom
patient
kidney
jejunum
mesenter
lymph
node
chronic
anicter
hcpatiti
patient
refcr
n
none
fluoresc
granul
detect
recent
nowoelawski
e
nl
report
studi
livcr
cell
obtain
autopsi
patient
lymphoprolif
disord
six
whosc
serum
contain
au
antigen
show
specif
nuclear
andor
cytoplasm
immunofluoresc
also
diamet
particl
sometim
chain
within
nuclei
six
auserum
show
neither
specif
immunofluoresc
intranuclear
particl
method
use
origin
detect
au
antigen
antibodi
serum
still
perhap
wide
use
twodimension
doubl
immunodiff
usion
recent
serolog
techniqu
differ
attribut
sensit
specif
turn
advantag
connect
viz
complement
fixat
cf
immunofluoresc
revers
passiv
hemagglutin
rpha
antibodyco
red
cell
immun
electron
microscopi
iem
immunoelectroosmophoresi
ieop
radioimmunoassay
ria
virtu
first
identif
character
au
antigen
antibodi
defin
term
precipit
reactant
use
blumberg
colleagu
subsequ
reactant
refer
like
manner
doubt
discrep
aris
use
serolog
procedur
demand
resolut
comparison
result
obtain
id
antigen
reactant
consist
princip
sera
fraction
deriv
therefrom
also
cell
either
natur
infect
experiment
expos
antibodi
reactant
compris
human
sera
sera
anim
hyperiinmun
whole
serum
fraction
contain
au
antigen
human
sera
antiau
precipitin
come
multipl
transfus
patient
eg
hemophilia
variou
kind
anemia
patient
hemodialysi
chronic
renal
diseas
cours
period
transfus
patient
presum
receiv
repeat
perhap
rather
small
stimuli
au
antigen
result
react
immun
protein
rather
infect
agent
respond
antibodi
instead
antigen
format
anim
use
includ
rabbit
guinea
pig
mice
rabbit
melartin
bluinberg
given
intramuscular
inject
alurnprecipit
au
serum
follow
similar
inject
week
inter
arid
intraperiton
inject
day
serum
collect
day
third
inject
two
week
rest
immun
schedul
repeat
result
antisera
requir
absorpt
auhuman
serum
remov
antibodi
normal
compon
guinea
pig
rabbit
purcel
et
nl
immun
au
serum
fraction
separ
two
cscl
densiti
gradient
centrifugatioii
follow
rate
sediment
sucros
antigen
prepar
emulsifi
freund
cornpletc
adjuv
inject
footpad
boost
inject
aqueou
immunogen
given
subcutan
interv
start
week
initi
inject
anim
receiv
purifi
au
fraction
rabbit
respond
poor
antiau
antibodi
format
also
develop
low
level
antibodi
normal
serum
compon
guinea
pig
howev
produc
good
level
seemingli
unispecif
antiau
antibodi
respons
serum
compon
ascit
fluid
obtain
immun
mice
without
aid
ascit
tumor
cell
hierholz
laboratori
inject
mice
intraperiton
au
fraction
prepar
describ
guinea
pig
mix
freund
complet
adjuv
follow
similar
booster
inject
footpad
week
later
week
mice
given
ascit
tumor
cell
sarcoma
ascit
fluid
tap
week
inject
tumor
cell
thereaft
everi
day
week
time
mice
die
tumor
moder
level
antiau
antibodi
dctect
cf
id
second
booster
inject
fluid
far
obtain
usual
contain
low
level
nonau
antibodi
requir
ahsorpt
normal
human
serum
millman
ef
produc
immun
ascit
fluid
inject
ail
serum
freund
complet
adjuv
without
tumor
cell
proport
part
adjuv
serum
later
reduc
l
first
iiitraperitorir
inject
l
second
given
week
later
half
mice
develop
ascit
week
second
inject
rate
fluid
product
could
increas
period
intraperiton
inject
salineadjuv
mixtur
h
r
b
nonspecif
antibodi
fluid
mix
normal
human
serum
els
test
well
riorin
serum
previous
allowcd
diffus
agar
inwel
absorpt
sera
judg
au
human
antiserum
also
react
ascit
fluid
besid
sera
au
human
antiserum
other
react
ascit
fluid
au
sera
gave
two
precipit
band
sever
mous
fluid
yet
one
human
rabbit
antisera
treatment
ascit
fluid
well
exclus
chromatographi
sephadex
indic
appreci
part
mous
antibodi
appar
igm
class
fluid
give
two
band
treat
mercaptoethanol
one
band
longer
seen
suggest
serolog
nonident
human
certain
mous
antibodi
discuss
p
twodimension
doubl
diffus
procedur
base
method
ouchterloni
princ
increas
sensit
antigen
detect
modifi
techniqu
use
agaros
made
nacl
buffer
tri
ph
c
ad
protamin
sulfat
ethylenediaminetetraacet
acid
gel
protamin
sulfat
caus
cloud
gel
occasion
format
obscur
halo
opac
accordingli
omit
laboratori
n
experi
singl
import
factor
improv
detect
tenuou
precipit
band
use
clear
agaros
concentr
exceed
wv
exact
buffer
use
appear
less
critic
except
prefer
exclud
phosphat
use
buffer
ph
tri
contain
wv
sodium
azid
preserv
question
standard
measur
unusu
virolog
applic
id
scarc
broach
let
alon
settl
blumberg
colleagu
employ
tube
method
preer
preer
quantit
au
antigen
concentr
test
sera
unknown
sera
test
parallel
undilut
standard
antiserum
content
au
antigen
express
preer
unit
depend
distanc
precipit
antigenagar
interfac
fix
time
purpos
column
agar
reaction
tube
divid
unit
n
laboratori
provision
method
assay
roughli
quantit
approach
use
measur
polioviru
rubella
viru
antigen
le
bouvier
appli
estim
au
antigen
antibodi
one
serum
pool
contain
au
antigen
one
contain
antiau
antibodi
select
refer
standard
posit
equival
au
system
found
distanc
au
antigen
cup
homolog
antibodi
cup
posit
lead
edg
precipit
form
variou
interact
pair
antigen
antibodi
dilut
measur
photograph
standard
curv
drawn
highest
dilut
standard
antibodi
reactant
still
give
distinct
band
precipit
equival
zone
dilut
standard
auspecif
antigen
reactant
defin
contain
yale
unit
antiau
precipitin
per
pl
particular
dilut
antigen
prepar
gave
precipit
taken
contain
yale
unit
au
precipit
antigen
per
pl
unknown
reactant
compar
standard
antigen
antibodi
content
similarli
express
yale
unit
per
strength
au
precipit
antigen
also
measur
make
serial
dilut
sera
test
determin
titer
highest
dilut
still
give
detect
precipit
undefin
rel
high
concentr
antibodi
reactant
factor
may
help
enhanc
sensit
id
test
includ
utmost
possibl
clariti
gel
reason
close
space
cup
use
larger
cup
sera
test
suspect
minim
level
antigen
antibodi
prefil
cup
unknown
reactant
hour
disposit
standard
reactant
time
test
cup
refil
use
standard
antigen
antibodi
reactant
approxim
equival
proport
concentr
adequ
give
clear
arc
precipit
whose
end
approach
cup
contain
unknown
reactant
strong
weak
reaction
given
unknown
sera
forc
back
cup
pattern
adopt
familiar
hexagon
arrang
seri
fuse
hexagon
becom
effect
middl
row
altern
cup
antigen
antibodi
standard
flank
two
row
cup
contain
unknown
reactant
greater
sensit
cf
compar
id
led
use
studi
au
system
kind
cf
test
unknown
materi
test
specif
posit
reactant
appropri
neg
controlantigen
antibodi
case
may
n
au
system
antigen
sought
present
among
rich
assort
normal
serum
compon
necessari
know
standard
antibodi
reactant
fix
complement
antigen
human
sera
contain
antiau
antibodi
may
safest
reactant
purpos
clear
mani
sera
repeatedli
stimul
donor
may
contain
varieti
antibodi
differ
serum
compon
anim
hyperimmun
antisera
would
seem
prefer
ideal
control
antiserum
also
prepar
earli
auserum
specimen
taken
individu
provid
au
serum
serv
either
fraction
sourc
immun
antigen
type
cf
test
use
detect
mcasurc
au
antigen
antibodi
includ
rel
simpl
linear
test
dilut
unknown
serum
test
optim
concentr
known
antiau
antibodi
select
dose
complement
cf
purcel
et
al
twodimension
test
standard
chessboard
type
serial
dilut
antigen
antibodi
reactant
test
use
singl
dose
complement
test
quantit
cf
unknown
serum
test
dilut
singl
optim
concentr
known
serumeith
antigcn
antibodi
sourc
case
may
beand
amount
complement
fix
determin
cf
shulman
threedimension
test
concentr
antigen
antibodi
complement
vari
curv
drawn
total
amount
complement
fix
vari
combin
standard
unknown
reactant
conveni
strength
unknown
serum
test
may
also
given
highest
dilut
fix
chosen
dose
complement
eg
two
hemolyt
unit
presenc
optim
standard
antigen
antibodi
case
may
wherea
id
test
may
set
detect
antigen
antibodi
reactiv
unknown
sampl
cf
test
cours
usual
design
look
one
activ
id
test
advantag
cf
test
confirm
refut
ab
initio
au
ident
antigen
antibodi
detect
unknown
serum
inher
less
sensit
dispar
sensit
increas
size
react
particl
must
diffus
gel
id
test
compar
studi
purcel
et
al
linear
cf
test
employ
time
sensit
id
detect
au
antigen
time
sensit
detect
antibodi
use
modifi
princ
method
id
protamin
sulfat
omit
gel
shulman
comparison
complement
consumpt
test
time
better
id
procedur
cletect
au
antigen
quit
remark
degre
superior
seri
hierholz
le
bouvier
employ
linear
c
f
test
two
unit
complement
differ
time
favor
cf
detect
au
antigen
time
differ
abil
detect
antiau
antibodi
sometim
id
method
appear
slightli
time
sensit
c
f
purpos
perhap
greatest
success
cf
serolog
studi
sh
infect
identif
shulman
barker
transient
phase
later
part
incub
period
case
patient
serum
becom
anticomplementari
ac
ac
activ
rise
peak
week
infect
declin
time
free
ali
antigen
first
becom
detect
serum
n
case
second
ac
phase
seen
free
au
antigen
ceas
detect
serum
sometim
anticomplementari
serolog
anomali
observ
suspect
appar
ac
effect
might
fact
due
actual
fixat
complement
result
simultan
presenc
circul
antigen
antibodi
format
immun
complex
confirm
find
addit
known
au
antigen
antibodi
serum
question
produc
situat
antigen
antibodi
excess
consequ
prozon
diminish
cf
auspecif
charact
ac
activ
shown
fraction
sera
cscl
gradient
find
au
particl
appar
coat
antibodi
ac
fraction
treatment
fraction
fluorocarbon
dissoci
virusantibodi
complex
reduc
elimin
ac
activ
often
doubl
auantigen
activ
detect
addit
known
antibodi
au
antigen
especi
experiment
system
known
antigen
antibodi
reactant
manipul
consequ
assess
detect
weakli
antigenposit
sera
also
come
may
occasion
situat
unispecif
reaction
may
need
corrobor
id
perhap
c
f
crosstest
absorpt
standard
antiserum
standard
unknown
antigen
reactant
presenc
au
antigenantibodi
complex
serum
patient
hepat
also
demonstr
electron
microscop
almcitla
waterson
use
techniqu
neg
stain
phosphotungst
acid
vide
supra
p
describ
find
differ
type
individu
chronic
asymptomat
carrier
au
antigen
whose
serum
randomli
distribut
spheric
tubular
particl
seen
sign
aggreg
evid
antibodi
molecul
attach
particl
patient
chronic
activ
hepat
possess
mani
pleomorph
tubular
well
spheric
form
singl
particl
aggreg
present
appar
compris
sever
hundr
particl
fatal
case
acut
hepat
whose
serum
contain
elong
form
mani
characterist
spheric
particl
coat
larg
amount
antibodi
form
numer
aggreg
quit
small
size
symptomless
carrier
exhibit
condit
persist
appar
toler
carriag
au
particl
without
product
antiau
antibodi
chronic
activ
hepat
case
evid
possess
au
antigen
excess
succeed
elabor
minut
amount
antibodi
n
fulmin
case
appar
antiau
antibodi
present
excess
author
discuss
possibl
signific
divers
rel
proport
au
antigen
antibodi
dissimilar
type
case
suggest
analog
acut
sh
serum
sick
shown
caus
immun
complex
present
circul
dixon
excess
antibodi
may
lead
anaphylact
reaction
though
fail
remov
circul
antigen
chronic
case
larg
immun
complex
seen
capabl
initi
degen
chang
liver
organ
perhap
persist
carrier
state
symbiosi
mutual
forbear
seem
achiev
neither
obviou
reaction
au
antigen
detect
patholog
host
find
consid
conclud
discuss
use
millman
et
al
identif
au
antigen
liver
biopsi
cell
case
hepat
mention
p
second
paper
author
coyn
et
al
extend
substanti
earlier
find
studi
patient
varieti
diseas
includ
evid
viral
hepat
au
antigen
serum
show
posit
reaction
au
antigen
biopsi
liver
cell
remain
patient
au
antigen
seruman
inmat
mental
institut
patient
chronic
renal
diseas
receiv
mani
blood
transfus
addit
patient
liver
biopsi
diagnos
includ
postnecrot
biliari
cirrhosi
biliari
atresia
bile
duct
carcinoma
hepat
metastasi
renal
carcinoma
cell
smear
prepar
minc
liver
specimen
spread
drop
result
suspens
slide
fix
aceton
stain
directli
fluoresceinlabel
rabbit
antiserum
posit
reaction
took
form
discret
particl
within
nucleu
diffus
fluoresc
whole
nucleu
fluoresc
nuclear
rim
occasion
particl
fluoresc
antigen
also
seen
cytoplasm
variou
tissu
examin
thc
posit
find
cell
bone
marrow
hepat
patient
antigen
liver
spleen
mesenteri
testi
patient
chronic
hepat
die
acut
myeloid
leukemia
cell
origin
includ
buffi
coat
cell
cell
peripher
lymphocyt
cultur
uniformli
neg
au
antigen
techniqu
would
particular
valu
observ
exposur
cell
cultur
au
antigen
follow
subsequ
event
includ
potenti
synthesi
new
au
antigen
sever
worker
attempt
studi
definit
result
still
await
ingeni
slide
test
au
antigen
devis
purcel
larg
drop
blood
serum
test
spread
film
glass
slide
allow
dri
fix
aceton
minut
room
temperatur
airdri
uninactiv
guinea
pig
sera
without
antiau
antibodi
spread
part
film
allow
stand
contact
minut
c
remov
slide
wash
sever
time
phosphatebuff
salin
pb
ph
expos
fluoresceinlabel
hors
antiguinea
pig
globulin
wash
examin
lowpow
object
specimen
contain
au
antigen
fluoresc
vari
intens
show
numer
bright
point
light
serum
phase
intact
form
element
blood
show
stain
au
antigen
content
sera
roughli
quantit
test
drop
serial
dilut
way
juji
yokochi
made
au
antigenantibodi
precipit
wash
treat
nai
dissoci
antiau
antibodi
final
separ
recov
exclus
chromatographi
sephadex
equilibr
nai
dialysi
pb
antibodi
use
coat
human
group
rhposit
red
cell
prepar
treatment
formalin
tannic
acid
control
red
cell
coat
normal
human
use
detector
au
antigen
antibodyco
red
cell
suspend
concentr
pb
ph
contain
normal
rabbit
serum
ha
test
done
microtit
method
consid
sensit
id
detect
au
antigen
fiftyfour
assort
sera
au
viral
hepat
sera
au
id
test
rpha
control
antiauco
red
cell
four
au
sera
agglutin
control
red
cell
readili
test
cell
au
sera
ha
titer
antibodyco
cell
least
time
higher
hand
auhepat
sera
hemagglutin
titer
antibodyco
cell
consid
significantli
higher
time
titer
control
cell
method
yet
tri
detect
antibodi
help
cell
coat
au
particl
solubil
fraction
thereof
unfortun
antibodyco
erythrocyt
far
prove
unstabl
becom
denatur
within
week
n
theori
could
repres
sensit
rel
simpl
way
detect
either
antigen
antibodi
perhap
modif
procedur
eg
substitut
activ
sepharos
anoth
suitabl
immunoadsorb
vehicl
might
provid
stabl
test
suspens
techniqu
ieop
introduc
princ
princ
burk
merril
et
al
attempt
increas
speed
sensit
screen
potenti
blood
donor
presenc
au
antigen
involv
forc
diffus
sera
test
gel
antibodi
reactant
either
incorpor
els
place
multipl
cup
trough
method
therefor
much
time
expens
standard
antiserum
usual
immunodiffus
procedur
howev
appar
detect
time
mani
au
donor
id
ie
everi
commerci
donor
estim
probabl
carrier
sh
agent
group
princ
burk
techniqu
critic
depend
number
factor
includ
temperatur
ph
type
buffer
ionic
strength
voltag
reliabl
standard
control
tendenc
nonspecif
precipit
minim
may
prove
method
choic
donor
screen
especi
sinc
result
avail
within
hour
n
quest
method
sensit
cf
abil
detect
au
antigen
especi
serum
prospect
blood
donor
worker
two
laboratori
walsh
et
al
coller
millnian
recent
report
success
applic
radioimmunoassay
procedur
alreadi
prove
use
measur
hormon
entail
prepar
purifi
au
antigen
radioact
label
purif
au
antigen
serum
effect
either
two
equilibrium
centrifug
cscl
follow
rate
separ
sucros
gerin
et
al
enzymat
treatment
au
particl
concentr
spin
follow
gcl
filtrat
sephadex
veloc
sediment
sucros
gradient
centrifug
equilibrium
cscl
millman
et
al
label
radioiodin
walsh
et
al
refraction
conjug
au
particl
sephadex
column
determin
peak
radioact
immunoreact
radioimmunodiffus
found
present
albumin
iodid
fraction
immunoreact
togeth
origin
label
emerg
void
volum
preliminari
standard
mixtur
contain
constant
amount
radioiodin
au
antigen
standard
antiau
antibodi
reactant
combin
vari
amount
select
unlabel
auposit
serum
effect
differ
concentr
unlabel
antigen
block
immun
aggreg
measur
deterniin
distribut
radioact
count
precipit
supernat
separ
eg
sediment
chromatoelectrophoresi
berson
et
al
walsh
e
al
use
au
serum
design
ijm
assign
potenc
jm
unit
antigen
per
millilit
deriv
standard
curv
plot
ratio
bf
antibodybound
l
b
free
l
f
function
concentr
standard
au
antigen
jm
show
mark
chang
bf
rang
au
antigen
concentr
j
unitsml
reduct
bf
correspond
increas
au
j
unitsml
antigen
concentr
gradual
declin
valu
bf
evid
therefor
thc
method
particularli
sensit
measur
differ
au
antigen
content
unknown
specimen
antigen
present
concentr
equival
dilut
standard
j
serum
titer
serum
c
f
indic
radioimmunoassay
method
time
sensit
detect
antigen
c
f
techniqu
use
walsh
e
al
separ
antigenantibodi
complex
chromatoelectrophoresi
berson
e
al
separ
bound
includ
solubl
immun
complex
coller
millman
precipit
antibodi
rabbit
antiserum
human
igg
measur
amount
radioact
antigen
precipit
way
sera
cf
titer
found
radioimmunoprecipit
equival
titer
antibodi
could
still
detect
serum
dilut
group
worker
shown
method
ria
thu
measur
au
antigen
antiau
antibodi
concentr
detect
cf
let
alon
id
also
show
concurr
presenc
antigen
antibodi
given
serum
case
bind
observ
control
without
ad
antiau
walsh
et
al
method
appear
hold
great
promis
sensit
mean
far
avail
detect
quantit
exigu
amount
au
antigen
antibodi
australia
particl
n
view
moder
complex
natur
au
particl
would
hardli
surpris
found
carri
antigen
determin
site
addit
seemingli
singl
one
far
firmli
establish
could
present
particl
surfac
epitop
mask
wait
reveal
suitabl
treatment
hypotop
n
addit
polypeptid
result
particl
protein
disrupt
eg
sodium
dodecyl
sulphat
treatment
may
expect
antigen
individu
cryptotop
appropri
hyperimmun
sera
prepar
first
find
suggest
multipl
antigen
specif
obtain
leven
blumberg
hyperimmun
rabbit
differ
antigen
prepar
au
serumcontain
au
patient
leukemia
serum
patient
leukem
reticuloendotheliosi
given
unusu
inconsist
reaction
aforement
antiau
antiserum
antiserum
prepar
second
human
serum
call
antiau
test
variou
combin
antigencontain
sera
two
antibodi
reactant
author
conclud
least
distinct
epitop
involv
design
b
c
antiau
serum
identifi
c
antiau
b
proceed
test
sera
differ
popul
two
antisera
obtain
markedli
diverg
result
shown
accompani
tabl
two
rabbit
antisera
use
dilut
select
give
roughli
compar
concentr
unshar
antibodi
specif
antib
antic
antigen
specif
b
present
express
serum
far
frequent
specif
c
howev
reaction
specif
would
blur
pictur
author
absorb
antisera
tri
obtain
unispecif
antib
antic
reactant
determin
whether
epitop
b
c
case
may
present
togeth
epitop
particl
whether
least
two
popul
particl
involv
millman
et
al
provid
inform
concern
antigen
complex
au
particl
reflect
antibodi
elicit
hyperimrnun
anim
found
previous
describ
antiau
activ
leven
decreas
time
storag
frozen
state
disappear
immun
rabbit
reinject
au
antigen
moreov
could
found
igg
fraction
elut
deaesephadex
howev
appar
demonstr
directli
igm
fraction
point
ascit
fluid
immun
mice
see
p
gener
h
w
e
reaction
ident
human
rabbit
antisera
found
react
sera
gave
posit
au
reaction
human
antiserum
six
sera
found
react
mous
ascit
fluid
human
antiserum
chromatographi
deaesephadex
gel
filtrat
sephadex
antiau
activ
demonstr
appar
igm
well
igg
fraction
sever
fluid
form
two
band
precipit
certain
au
human
sera
although
sera
gave
one
band
antibodi
reactant
two
antigen
concern
migrat
two
antibodi
remov
one
ascit
fluid
absorpt
normal
human
serum
treatment
fluid
mercaptoethanol
elimin
one
antibodi
data
interpret
addit
evid
multipl
specif
among
popul
antibodi
react
au
particl
howev
separ
ident
antigen
yet
shown
absorpt
test
possibl
physic
fraction
possibl
indic
antigen
complex
found
millman
et
al
suspens
au
particl
purifi
enzym
digest
gel
filtrat
zonal
isopycn
centrifug
treatment
ether
chloroform
hour
room
temperatur
suspens
gave
two
precipit
band
human
rabbit
antiau
antiserum
previous
given
one
one
two
band
appear
common
etherand
chloroformtr
au
particl
concentr
band
case
distinct
cross
reaction
nonident
experi
progress
laboratori
likewis
point
dissect
action
trypsin
au
antigen
exposur
au
serum
wv
trypsin
hour
caus
progress
degrad
sensit
compon
leav
rel
trypsinresist
compon
r
react
certain
human
antiau
sera
rabbit
mous
antiau
antiserum
kindli
suppli
dr
b
blumberg
guinea
pig
antiserum
gener
provid
dr
r
h
purcel
compon
would
therefor
appear
au
antigen
gener
recogn
specif
precis
natur
relationship
r
compon
remain
establish
blumberg
cowork
observ
presenc
au
antigen
serum
patient
hepat
presum
viral
origin
blumberg
et
al
princ
subsequ
worker
see
section
demonstr
appear
antigen
late
incub
period
sh
distinct
ih
transient
presenc
case
appar
toler
persist
follow
section
deal
problem
immunolog
respons
elicit
agent
sh
respons
appear
au
antigen
serum
consist
last
product
high
level
antibodi
signific
immun
complex
detect
acut
phase
later
stage
diseas
evid
concern
stimul
cellmedi
immun
relationship
cours
infect
antibodi
respons
au
antigen
depend
upon
method
stimul
prcsumabl
dosag
antigen
n
repeatedli
transfus
patient
rel
small
amount
au
antigen
togeth
subinfecti
concentr
activ
sh
agent
administ
interv
result
immun
recipi
effect
inert
lipoprotein
antigen
prepar
result
usual
process
infect
product
au
antigen
instead
elabor
antiau
antibodi
sera
examin
antibodi
resembl
igg
size
one
serum
half
molecular
weight
conceiv
earli
stage
immun
igm
antibodi
may
made
everi
case
n
patient
undergo
shagent
infect
appear
antiau
antibodi
may
beand
perhap
regularli
ismad
middl
incub
period
gener
detect
free
form
complex
antigen
produc
specif
anticomplementari
patient
serum
vide
supra
shulman
barker
found
anticomplementari
ac
activ
usual
transient
preced
appear
free
au
antigen
serum
though
could
also
coexist
appear
occur
without
detect
free
au
antigen
purcel
et
al
report
ac
activ
hepat
patient
tempor
relat
diseas
declin
without
replac
free
au
one
patient
ac
activ
free
au
antigen
develop
concurr
au
antigenantibodi
complex
would
cours
detect
id
unless
dissoci
test
shown
vide
infra
section
c
complex
seen
electron
microscop
case
acut
hepat
case
month
au
antigen
declin
disappear
free
antiau
cf
antibodi
ephemer
detect
n
least
one
patient
two
cycl
free
antigen
free
antibodi
succeed
one
anoth
period
week
krugman
gile
n
gener
howev
free
antiau
antibodi
evid
sh
infect
hyperimmun
recipi
au
blood
transfus
n
two
recipi
larg
amount
blood
unit
respect
antibodi
initi
detect
sharp
rise
antiau
c
f
antibodi
took
place
within
week
transfus
suggest
previou
sublimin
sensit
au
antigen
secondari
antibodi
respons
restimul
holland
et
ul
patient
chronic
activ
hepat
evid
sma
behav
way
antibodi
au
antigen
find
taken
suggest
may
least
two
etiolog
distinct
form
cah
diseas
initi
sh
agent
product
au
antigen
may
perpetu
mechan
autoimmun
process
presenc
circul
au
particleantibodi
aggreg
acut
viral
hepat
mention
see
section
v
e
n
fulmin
case
describ
aggreg
compar
small
eg
particl
often
l
particl
includ
unaggreg
one
seen
coat
ampl
suppli
igg
antibodi
molecul
therefor
situat
appear
one
antibodi
excess
author
also
report
em
find
serum
case
patient
chronic
activ
hepat
minor
recurr
symptom
rais
fluctuat
transaminas
level
asymptomat
individu
manifest
persist
appar
toler
infect
sh
agent
result
continu
presenc
high
level
au
antigen
serum
former
case
antibodi
continu
made
caus
format
larg
aggreg
spheric
tubular
au
particl
togeth
free
particl
coat
antibodi
pictur
one
antigen
excess
n
persist
carrier
au
particl
free
uniformli
dispers
without
evid
attach
antibodi
millman
et
al
demonstr
presenc
au
antigenantibodi
complex
serum
two
individu
one
case
acut
viral
hepat
antigen
could
detect
id
mental
retard
patient
antibodi
antibodi
separ
low
affin
complex
centrifug
high
affin
complex
treatment
seri
proteolyt
enzym
suggest
au
complex
may
present
stage
individu
free
antigen
antibodi
detect
question
cellular
immun
relat
au
antigen
far
receiv
littl
attent
earlier
studi
mella
lang
report
anerg
respons
phytohemagglutinin
pha
cultur
peripher
lymphocyt
case
acut
infecti
hepat
state
whether
rose
convalesc
time
variou
chromosom
anomali
develop
includ
sticki
multipl
break
delet
addit
willem
et
al
test
respons
pha
leukocyt
patient
viral
hepat
ih
sh
signific
depress
dna
synthesi
judg
hm
n
e
h
uptak
cell
day
cultur
medium
contain
fetal
calf
serum
day
incub
differ
control
earli
hyporespons
unalt
sera
healthi
donor
hepat
patient
ad
cultur
suggest
inher
cell
seen
sampl
taken
within
first
week
onset
jaundic
ih
sh
case
correl
sh
detect
au
antigen
serum
lack
lymphoblast
respons
pha
day
cultur
acut
phase
sera
two
ih
two
sh
patient
inhibit
pha
respons
normal
leukocyt
cultur
slightli
sera
healthi
donor
effect
could
serial
transmit
fresh
cultur
recent
agarw
et
al
also
confirm
diminish
respons
cultur
leukocyt
pha
measur
reduct
dna
polymeras
induct
incorpor
dna
patient
viral
hepat
unspecifi
type
scein
probabl
therefor
earli
sh
doc
regularli
develop
depress
ccllmediat
allerg
respons
remain
seen
similar
persist
anergi
demonstr
individu
go
becom
chronic
carrier
au
antigen
comprehens
comparison
appear
made
yet
determin
occurr
auspecif
distinct
gener
anergi
differ
kind
phase
shagent
infect
topic
discuss
section
vii
see
p
although
au
particl
seem
act
potent
stimul
humor
immun
must
rememb
enorm
concentr
avail
circul
antigen
estim
pgml
serum
would
adequ
sequestr
larg
amount
antibodi
n
case
immun
aggreg
visibl
concentr
circul
antigen
fall
rel
soon
quit
probabl
activ
cellular
allergi
also
elicit
least
proport
chronic
particl
carrier
hand
would
appear
format
antiau
antibodi
suppress
state
toler
induc
sinc
usual
state
split
toler
find
continu
antibodi
synthesi
absenc
cellmedi
reactiv
seem
like
persist
possessor
au
antigen
cellular
allerg
respons
likewis
suppress
situat
obtain
analog
mice
persist
tolerantli
infect
lymphocyt
choriomening
viru
cf
volkert
larsen
longer
seriou
doubt
synthesi
au
antigen
appear
serum
specif
associ
infect
causal
agent
sh
type
viral
hepat
precis
relationship
auantigen
particl
infecti
agent
still
settl
appear
main
possibl
smallest
unit
monad
see
ie
nm
modal
diamet
may
repres
viru
particl
presum
minor
would
possess
full
complement
nucleic
acid
rel
high
densiti
infect
elong
form
would
fact
aberr
analog
seen
exampl
among
papovavirus
particl
would
repres
incomplet
virion
even
fragment
viral
envelop
similar
myxoor
herpesvirus
infecti
unit
would
consist
rare
rel
dens
complet
particl
contain
nucleocapsid
within
membran
envelop
infecti
entiti
may
orthodox
type
virion
rather
kind
selfrepl
macromolecul
eg
unit
lipoprotein
membran
associ
carbohydr
residu
devoid
essenti
nucleic
acid
one
form
suggest
agent
scrapi
gibbon
hunter
auantigen
particl
may
bear
structur
relationship
whatev
sh
infecti
agent
may
new
modifi
cellular
compon
whose
synthesi
specifi
specif
derepress
infect
viru
present
time
possibl
choos
differ
hypothes
answer
varieti
question
hereaft
adumbr
affect
balanc
favor
small
proport
particl
found
contain
signific
amount
ribonucl
andor
deoxyribonucl
acid
infect
associ
fraction
rather
less
dens
fraction
compris
bulk
au
particl
variou
form
treatment
eg
heat
ultraviolet
irradi
enzym
digest
extract
lipid
solvent
exposur
sulfhydryl
reagent
period
leav
infect
essenti
undiminish
signific
reduct
titer
infect
antigen
reactiv
still
demonstr
subparticul
fraction
macromolecul
normal
liver
cell
detect
particl
possess
au
antigen
reactiv
signific
rel
larg
particl
report
dane
et
al
other
see
section
iv
apart
usual
smaller
auantigen
particl
morpholog
entiti
discern
sera
sh
patient
eg
compar
coronaviruslik
particl
seen
serum
certain
case
auchron
activ
hepat
zuckerman
et
al
also
sera
healthi
individu
deinhardt
et
al
clearli
essenti
prerequisit
studi
kind
rel
simpl
reproduc
test
infect
either
vivo
witro
hope
cultur
manipul
cell
differ
biopsi
tissu
includ
cocultiv
perhap
impos
fusion
divers
indic
cell
organ
explant
possibl
also
mainten
heterotranspl
may
permit
au
synthet
activ
infecti
agent
express
recogn
inde
bang
ask
comment
hypothesi
persist
carriag
au
antigen
genet
determin
man
thc
mous
specif
cellular
basi
inherit
resist
suscept
infectionand
diseascaus
hepat
virus
concern
pathogenesi
sh
attent
drawn
possibl
role
circul
antigenantibodi
aggreg
sinc
evid
acut
chronic
diseas
seen
asymptomat
persist
carrier
au
antigen
au
particl
produc
hepat
perhap
also
lymphorcticular
cell
immun
complex
might
expect
pass
pulmonari
capillari
retain
system
circul
lodg
peripher
capillari
eg
skin
central
nervou
system
especi
renal
glomeruli
appear
report
yet
lesion
relat
possibl
capillari
trap
aggreg
presenc
au
antigen
antibodi
situat
case
chronic
hepat
whether
activ
aggress
type
later
stage
rel
benign
persist
form
patholog
might
well
look
follow
model
mice
persist
infect
lcm
viru
continu
slowli
develop
product
antibodi
result
format
virusantibodi
complex
consequ
late
diseas
chronic
glomerulonephr
hotchin
collin
oldston
dixon
probabl
even
import
circul
antibodi
potenti
pathogenet
factor
viral
hepat
cellmedi
allerg
respons
seem
clear
persist
possessor
serum
au
antigen
must
rather
firmli
found
state
toler
involv
antibodi
synthet
mechan
also
presum
cellular
immun
mechan
respons
delayedtyp
hypersensit
reject
antigen
foreign
alter
cell
sinc
precis
chronic
carrier
larg
concentr
au
particl
lack
detect
allerg
respons
remain
free
overt
diseas
suspicion
direct
toward
respons
probabl
essenti
particip
vari
degre
hepat
cell
destruct
lead
elev
serum
transaminas
symptom
sign
anicter
hepat
fullblown
icter
diseas
follow
model
therefor
put
forward
explain
differ
manifest
infect
caus
au
antigeninduc
agent
sh
around
middl
incub
period
eg
week
inocul
infect
cell
liver
perhap
elsewher
begin
synthes
new
macromolecul
au
antigen
specif
either
virion
virusassoci
lipoprotein
particl
antigen
alter
cellmembran
fragment
releas
circul
extent
disintegr
suscept
heavili
infect
cell
princip
shed
bud
cell
otherwis
continu
function
rel
normal
number
disrupt
cell
increas
serum
transaminas
level
rise
howev
stage
clinic
symptom
patient
remain
symptomfre
long
allerg
respons
remain
minim
impercept
mani
case
firstform
au
antigen
alreadi
evok
low
concentr
specif
antiau
antibodi
becom
bound
grow
number
au
particl
antibodi
soon
declin
follow
excess
free
au
antigen
serum
gener
fall
away
turn
within
day
week
case
detect
usual
transient
resurg
antibodi
begin
circul
unbound
form
n
other
may
bc
sublimin
level
antibodi
low
pick
method
detect
present
avail
patient
earlier
phase
anticomplementari
immun
complex
serum
yet
show
symptom
hepat
despit
possess
bound
sometim
also
free
antibodi
therefor
suggest
actual
clinicnl
diseas
result
cellmedi
allerg
respons
ayainst
infect
cell
process
produc
au
particl
whose
surfac
membran
possibl
also
intern
membran
acquir
specif
new
antigen
configur
activ
immunolog
attack
hepat
cell
would
lead
massiv
cytolysi
sign
symptom
indic
vari
degre
liver
dysfunct
n
mani
case
energet
reaction
assist
perhap
residu
antibodyproduc
capac
destroy
virusharbor
cell
termin
infect
outcom
usual
seen
rel
healthi
individu
eg
personnel
staff
renal
hemodialysi
unit
london
et
al
turner
white
contrast
individu
eg
patient
chronic
renal
diseas
undergo
hemodialysi
mayb
also
treatment
immunosuppress
agent
allerg
respons
may
depress
greater
lesser
degre
therefor
fail
elimin
infect
individu
go
becom
partial
case
total
toler
persist
carrier
sh
agent
au
particl
hallmark
n
vari
level
incomplet
toler
cellular
perhap
also
humor
respons
may
fluctuat
patient
would
expect
show
variat
level
serum
au
antigen
would
also
experi
correspond
exacerb
remiss
clinic
condit
perfect
unbroken
toler
smaller
would
clinic
disturb
continu
sustain
product
au
antigen
highli
toler
individu
sh
agent
might
inde
begin
behav
slow
virw
caus
gradual
progress
destruct
one
kind
tissu
either
replic
alon
help
period
local
minim
soon
circumscrib
allerg
reaction
differ
aspect
hypothet
model
though
still
part
untest
would
seem
consist
known
fact
point
sever
kind
approach
might
expect
shed
light
question
pathogenesi
studi
delayedtyp
hypersensit
reaction
vitro
lymphoblast
respons
differ
clinic
categori
stage
au
shagent
infect
